# TITLE: BLADDER CANCER CHEMOPREVENTION USING THE ANDROGEN RECEPTOR INHIBITOR APALUTAMIDE

> **NIH NIH N01** · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · 2022 · $1,046,094

## Abstract

Bladder cancer (BC) is the second-most common cancer of the genitourinary tract and also the major cause of death in patients. Preventing BC is highly desirable to reduce recurrence, mortality and improve quality of life. Preclinical and clinical data indicate the potential role of AR signaling in different stages of BC. In view of the strong link between AR signals and bladder cancer progression, apalutamide, a FDA approved next-generation AR antagonist, could provide a preventive strategy in NMIBC to mitigate progression to MIBC. The overall objective of this task order is to determine the efficacy of Apalutamide against N-butyl-N(4-hydroxybutyl) nitrosamine (BBN) induced rat urinary bladder cancers. The task order will assess welldefined predictive biomarkers of bladder cancer inhibition by apalutamide.

## Key facts

- **NIH application ID:** 10677989
- **Project number:** 75N91019D00020-0-759102200002-1
- **Recipient organization:** UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
- **Principal Investigator:** CHINTHALAPALLY RAO
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $1,046,094
- **Award type:** —
- **Project period:** 2022-08-05 → 2024-08-04

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10677989

## Citation

> US National Institutes of Health, RePORTER application 10677989, TITLE: BLADDER CANCER CHEMOPREVENTION USING THE ANDROGEN RECEPTOR INHIBITOR APALUTAMIDE (75N91019D00020-0-759102200002-1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10677989. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*